Anti-CTLA-4 therapy-associated granuloma annulare in chronic myelomonocytic leukemia
Claire J Wiggins1, Susan Y Chon1
1Department of Dermatology, M. D. Anderson Cancer Center, Houston, Texas.
Abstract:
Immune checkpoint inhibitor (ICI) therapies activate the immune system to unmask cancer cells that the body might otherwise not detect. These cancer therapies alter the immune system at different "checkpoint" proteins such as PD-1, PD-L1, or CTLA-4 to better target tumor cells, but also have the potential to affect normal tissues. In patients receiving ICI therapy, cutaneous reactions have been frequently documented, ranging from mild urticarial rashes to widespread cutaneous necrosis. Proper identification and management of ICI therapy side effects is essential to the care of these patients. Here, we present an unusual granulomatous cutaneous reaction in a patient receiving anti-CTLA-4 therapy for chronic myelomonocytic leukemia.
Insights
Immune checkpoint inhibitor (ICI) therapies can cause skin reactions. This study details a rare granulomatous reaction in a patient treated with anti-CTLA-4 therapy for chronic myelomonocytic leukemia.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Immune checkpoint inhibitors (ICIs) like anti-CTLA-4 therapy harness the immune system to combat cancer.
- While effective, ICIs can cause immune-related adverse events, including frequent cutaneous reactions.
- Managing these side effects is crucial for patient care.
Observation:
- A patient undergoing anti-CTLA-4 therapy for chronic myelomonocytic leukemia developed an unusual skin reaction.
- The observed reaction presented as a granulomatous cutaneous manifestation.
Findings:
- This case highlights a rare granulomatous skin reaction associated with anti-CTLA-4 therapy.
- The findings underscore the diverse range of dermatological side effects possible with ICI treatment.
Implications:
- Early recognition and management of ICI-induced cutaneous reactions are vital.
- This case expands the understanding of potential adverse events associated with immune checkpoint blockade.
- Further research into managing these specific granulomatous reactions may be warranted.
More Related Videos
07:17Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
Published on: August 23, 2024
06:35An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
